Maria J. Monasterio-Lafuente

Tres Cantos, MD 28760, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation.

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation.

Journal: ACS chemical biology

Published: June 13, 2026

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation.

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation.

Journal: bioRxiv : the preprint server for biology

Published: August 12, 2025

Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action.

Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action.

Journal: Research square

Published: October 14, 2024

Development of an ectopic huLiver model for Plasmodium liver stage infection.

Development of an ectopic huLiver model for Plasmodium liver stage infection.

Journal: PloS one

Published: November 29, 2022

Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance.

Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance.

Journal: eLife

Published: November 18, 2022

The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages.

The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages.

Journal: Science translational medicine

Published: October 19, 2022

Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.

Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.

Journal: Angewandte Chemie (International ed. in English)

Published: November 27, 2020

Disruption of the Plasmodium falciparum Life Cycle through Transcriptional Reprogramming by Inhibitors of Jumonji Demethylases.

Disruption of the Plasmodium falciparum Life Cycle through Transcriptional Reprogramming by Inhibitors of Jumonji Demethylases.

Journal: ACS infectious diseases

Published: April 10, 2020

Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.

Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.

Journal: Journal of medicinal chemistry

Published: April 07, 2020

Setting Our Sights on Infectious Diseases.

Setting Our Sights on Infectious Diseases.

Journal: ACS infectious diseases

Published: December 07, 2019

Fueling Open Innovation for Malaria Transmission-Blocking Drugs: Hundreds of Molecules Targeting Early Parasite Mosquito Stages.

Fueling Open Innovation for Malaria Transmission-Blocking Drugs: Hundreds of Molecules Targeting Early Parasite Mosquito Stages.

Journal: Frontiers in microbiology

Published: June 20, 2019

In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.

In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.

Journal: Science translational medicine

Published: August 20, 2018

Showing 1-12 of 31

Last Updated: 09/26/2026